One of the mechanisms involved in the progression of
diabetic nephropathy, the most common cause of
end-stage renal failure, is angiogenic phenomenon associated with the increase of angiogenic factors such as
vascular endothelial growth factor (
VEGF)-A and
angiopoietin (Ang)-2, an antagonist of Ang-1. In the present study, we examined the therapeutic efficacy of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)
propionic acid (NM-3), a small molecule
isocoumarin with antiangiogenic activity, using diabetic db/db mice, a model of obese
type 2 diabetes. Increases in kidney weight, glomerular volume,
creatinine clearance, urinary
albumin excretion, total mesangial fraction, glomerular
type IV collagen, glomerular endothelial area (CD31(+)), and monocyte/macrophage accumulation (F4/80(+)) observed in control db/db mice were significantly suppressed by daily
intraperitoneal injection of NM-3 (100 mg/kg, for 8 weeks). Increases in renal expression of
VEGF-A, Ang-2, fibrogenic
factor transforming growth factor (TGF)-beta1, and
chemokine monocyte chemoattractant protein-1 but not
tumor necrosis factor-alpha were also inhibited by NM-3 in db/db mice. Furthermore, decreases of
nephrin mRNA and
protein levels in db/db mice were recovered by NM-3. In addition, treatment of db/db mice with NM-3 did not affect
body weight,
blood glucose, serum
insulin, or food consumption. NM-3 significantly suppressed the increase of
VEGF induced by high
glucose in cultured podocytes and also suppressed the increase of
VEGF and
TGF-beta induced by high
glucose in cultured mesangial cells. Taken together, these results demonstrate the potential use of NM-3 as a novel therapeutic agent for renal alterations in
type 2 diabetes.